JPH0131388B2 - - Google Patents
Info
- Publication number
- JPH0131388B2 JPH0131388B2 JP57052671A JP5267182A JPH0131388B2 JP H0131388 B2 JPH0131388 B2 JP H0131388B2 JP 57052671 A JP57052671 A JP 57052671A JP 5267182 A JP5267182 A JP 5267182A JP H0131388 B2 JPH0131388 B2 JP H0131388B2
- Authority
- JP
- Japan
- Prior art keywords
- pressure
- sensitive adhesive
- drug
- adhesive layer
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 33
- 239000010410 layer Substances 0.000 claims description 31
- -1 acrylic ester Chemical class 0.000 claims description 25
- 239000002390 adhesive tape Substances 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 18
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 16
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 229960004025 sodium salicylate Drugs 0.000 description 15
- 159000000000 sodium salts Chemical class 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229960000905 indomethacin Drugs 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 5
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000005395 methacrylic acid group Chemical group 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- ZVYGIPWYVVJFRW-UHFFFAOYSA-N 3-methylbutyl prop-2-enoate Chemical compound CC(C)CCOC(=O)C=C ZVYGIPWYVVJFRW-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- YYQRGCZGSFRBAM-UHFFFAOYSA-N Triclofos Chemical class OP(O)(=O)OCC(Cl)(Cl)Cl YYQRGCZGSFRBAM-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- WXTSWQXFVGMLBW-AHUNZLEGSA-H [Au+3].[Au+3].[O-]C(=O)\C=C/C([O-])=S.[O-]C(=O)\C=C/C([O-])=S.[O-]C(=O)\C=C/C([O-])=S Chemical compound [Au+3].[Au+3].[O-]C(=O)\C=C/C([O-])=S.[O-]C(=O)\C=C/C([O-])=S.[O-]C(=O)\C=C/C([O-])=S WXTSWQXFVGMLBW-AHUNZLEGSA-H 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000012662 bulk polymerization Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- XDSGMUJLZDSCPA-UHFFFAOYSA-N diazanium;phenoxybenzene;sulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.C=1C=CC=CC=1OC1=CC=CC=C1 XDSGMUJLZDSCPA-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- JTNHOVZOOVVGHI-UHFFFAOYSA-N menadiol sodium diphosphate Chemical compound C1=CC=CC2=C(OP(O)(O)=O)C(C)=CC(OP(O)(O)=O)=C21 JTNHOVZOOVVGHI-UHFFFAOYSA-N 0.000 description 1
- XDPFHGWVCTXHDX-UHFFFAOYSA-M menadione sodium sulfonate Chemical compound [Na+].C1=CC=C2C(=O)C(C)(S([O-])(=O)=O)CC(=O)C2=C1 XDPFHGWVCTXHDX-UHFFFAOYSA-M 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical class [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical class 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960001147 triclofos Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Adhesive Tapes (AREA)
- Adhesives Or Adhesive Processes (AREA)
Description
【発明の詳細な説明】
本発明は治療用接着テープもしくはシートに関
する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to therapeutic adhesive tapes or sheets.
基材に、治療用薬剤を混入させた感圧性接着剤
層が薄層状に設けられた治療用接着テープもしく
はシートを被着体である皮膚に貼付け、感圧性接
着剤層から滲出する薬剤により局所治療を行なう
ことが、従来の密封包帯療法（ODT療法）に代
る新たな治療方法として注目されている。 A therapeutic adhesive tape or sheet with a thin layer of pressure-sensitive adhesive mixed with a therapeutic drug is applied to the skin as a base material, and the drug that exudes from the pressure-sensitive adhesive layer acts locally. This treatment is attracting attention as a new treatment method to replace the conventional occlusive dressing therapy (ODT therapy).
このような治療用接着テープもしくはシートに
要求される性能は、感圧性接着剤が皮膚に対し強
い刺激を与えないこと、皮膚に貼付しやすく剥す
に際して接着剤の皮膚への付着や過度な接着力に
より苦痛を与えないこと、感圧性接着剤と薬剤と
の間の相互化学作用がないこと、薬効が充分得ら
れるように薬剤が接着剤中から効果的に表面に滲
出しやすいこと等である。 The performance required for such therapeutic adhesive tapes or sheets is that the pressure-sensitive adhesive does not cause strong irritation to the skin, and that it is easy to apply to the skin and that it does not cause excessive adhesion to the skin when removed. There is no mutual chemical interaction between the pressure-sensitive adhesive and the drug, and the drug easily oozes out from the adhesive to the surface so that sufficient medicinal effects can be obtained.
ところで従来のこの種治療用接着テープもしく
はシートにおいては、基材上に形成された感圧性
接着剤層の表面に薬剤の溶液を塗布し次いでこれ
を乾操するか、又は、感圧性接着剤の溶液に薬剤
を混合したものを基材上に塗布し、乾操すること
により製造することが行なわれてきた。しかしな
がら前者の場合には、薬剤が感圧性接着剤層の表
面に塗布されているだけであるので患部へ急速に
吸収されてしまう欠点があり、又、後者の場合に
は感圧性接着剤中に混入したまゝで滲出され難
く、患部へ吸収されるのに非常に長時間を要する
欠点があり、いずれの場合においても患部へ好ま
しい速さで徐々に吸収されてゆくようにすること
は困難であつた。 By the way, in conventional therapeutic adhesive tapes or sheets of this type, a drug solution is applied to the surface of a pressure-sensitive adhesive layer formed on a base material and then dried, or a pressure-sensitive adhesive layer is coated with a solution of a drug and then dried. Manufacturing has been carried out by coating a mixture of a solution with a drug on a substrate and drying it. However, in the former case, the drug is applied only to the surface of the pressure-sensitive adhesive layer, which has the disadvantage that it is rapidly absorbed into the affected area; It has the disadvantage that it is difficult to exude when mixed in, and it takes a very long time for it to be absorbed into the affected area, and in either case, it is difficult to ensure that it is gradually absorbed into the affected area at a desirable rate. It was hot.
本発明はかゝる欠点を解消することを目的とし
てなされたものであり、薬剤が感圧性接着剤層か
ら徐々に滲出されて患部へ好ましい速度で吸収さ
れ、良好な治療効果を上げることができる治療用
接着テープもしくはシートを提供するものであ
る。 The present invention was made with the aim of eliminating such drawbacks, and the drug is gradually exuded from the pressure-sensitive adhesive layer and absorbed into the affected area at a preferable rate, resulting in good therapeutic effects. The present invention provides therapeutic adhesive tapes or sheets.
本発明の要旨は、基材に、アクリル酸エステル
又は（及び）メタクリル酸エスタルを構成成分と
する重合体よりなる感圧性接着剤層が設けられ、
該感圧性接着剤層に界面活性剤と、弱酸基又は強
酸基の金属塩を有する薬剤が含有されている。治
療用接着テープもしくはシートに存する。 The gist of the present invention is that a pressure-sensitive adhesive layer made of a polymer containing acrylic acid ester or (and) methacrylic acid ester as a constituent component is provided on a base material,
The pressure-sensitive adhesive layer contains a surfactant and a drug having a metal salt of a weak acid group or a strong acid group. Present in therapeutic adhesive tapes or sheets.
次に本発明治療用接着テープもしくはシートに
ついて更に詳細に説明する。 Next, the therapeutic adhesive tape or sheet of the present invention will be explained in more detail.
本発明に用いられる基材としては、ポリエチレ
ン、ポリプロピレン、エチレン−酢酸ビニル共重
合体、軟質ポリ塩化ビニル、セロハン等の可撓性
を有する材質からなるものが好適に使用される。
基材の厚みとしては0.02乃至0.15mmの範囲が好ま
しい。 The base material used in the present invention is preferably made of a flexible material such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer, soft polyvinyl chloride, cellophane, or the like.
The thickness of the base material is preferably in the range of 0.02 to 0.15 mm.
前記基材には必要に応じ感圧性接着剤層との密
着力を高めるために、コロナ放電処理、プラズマ
処理、下塗剤塗工等が施される。 The base material is subjected to corona discharge treatment, plasma treatment, primer coating, etc., if necessary, in order to increase the adhesion with the pressure-sensitive adhesive layer.
この基材に、アクリル酸エステル又は（及び）
メタクリル酸エステルを構成成分とする重合体よ
りなる感圧性接着剤層が設けられる。前記重合体
の構成成分となるアクリル酸エステル又は（及
び）メタクリル酸エステルにおけるエステル残基
としては、例えばメチル基、エチル基、プロピル
基、イソプロピル基、ｎ−ブチル基、イソブチル
基、ｎ−ペンチル基、イソペンチル基、２−メチ
ルブチル基、ｎ−ヘキシル基、２−メチルペンチ
ル基、３−メチルペンチル基、２−エチルブチル
基、ｎ−オクチル基、イソオクチル基、２−エチ
ルヘキシル基、ノニル基、ｎ−デシル基、ラウリ
ル基等である。そして特に好適なアクリル酸エス
テルとしては、エチルアクリレート、ｎ−ブチル
アクリレート、イソブチルアクリレート、イソア
ミルアクリレート、２−エチルヘキシルアクリレ
ート、ｎ−オクチルアクリレート、ラウリルアク
リレート等であり、またメタクリル酸エステルと
しては、メチルメタクリレート、ブチルメタクリ
レート、２−エチルヘキシルメタクリレート、ｎ
−オクチルメタクリレート、ラウリルメタクリレ
ート等である。 On this base material, acrylic ester or (and)
A pressure-sensitive adhesive layer made of a polymer containing methacrylic acid ester as a constituent component is provided. Examples of ester residues in the acrylic ester or (and) methacrylic ester that are constituent components of the polymer include methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, n-pentyl group. , isopentyl group, 2-methylbutyl group, n-hexyl group, 2-methylpentyl group, 3-methylpentyl group, 2-ethylbutyl group, n-octyl group, isooctyl group, 2-ethylhexyl group, nonyl group, n-decyl group group, lauryl group, etc. Particularly suitable acrylic esters include ethyl acrylate, n-butyl acrylate, isobutyl acrylate, isoamyl acrylate, 2-ethylhexyl acrylate, n-octyl acrylate, lauryl acrylate, etc., and methacrylic esters include methyl methacrylate, Butyl methacrylate, 2-ethylhexyl methacrylate, n
-octyl methacrylate, lauryl methacrylate, etc.
感圧性接着剤層を構成する重合体としては、ア
クリル酸エステルだけの重合体である場合、メタ
クリル酸エステルだけの重合体である場合、アク
リル酸エステルとメタクリル酸エステルの共重合
体である場合、アクリル酸エステルとこれと共重
合可能な他の単量体との共重合体である場合、メ
タクリル酸エステルとこれと共重合可能な他の単
量体との共重合体である場合、アクリル酸エステ
ルとメタクリル酸エステルとこれらと共重合可能
な他の単量体との共重合体である場合のいずれも
が使用できる。 The polymer constituting the pressure-sensitive adhesive layer is a polymer of only acrylic ester, a polymer of only methacrylic ester, a copolymer of acrylic ester and methacrylic ester, If it is a copolymer of an acrylic ester and another monomer that can be copolymerized with it, or if it is a copolymer of a methacrylic ester and another monomer that can be copolymerized with it, acrylic acid Any of copolymers of esters, methacrylic esters, and other monomers copolymerizable with these can be used.
アクリル酸エステル、メタクリル酸エステルと
共重合可能な他の単量体としては、例えば酢酸ビ
ニル、塩化ビニル、塩化ビニリデン、アクリロニ
トリル、ステレン、エチレン、プロピレン、ブタ
ジエン、イソプレン、アクリル酸、アクリルアミ
ド等が存する。 Examples of other monomers copolymerizable with acrylic esters and methacrylic esters include vinyl acetate, vinyl chloride, vinylidene chloride, acrylonitrile, sterene, ethylene, propylene, butadiene, isoprene, acrylic acid, and acrylamide.
感圧性接着剤が、アクリル酸エステル、又は
（及び）メタクリル酸エステルを構成成分とする
重合体とされるのは、これらが化学的活性基を有
しないため皮膚に対する強い刺激を与えないもの
とすることができ、又薬剤に対する相互作用によ
る薬効の低減を防ぎうることによる。またこのた
めには前記重合体が、アクリル酸エステル又は
（及び）メタクリル酸エステルとこれらと共重合
可能な他の単量体との共重合体の場合には、アク
リル酸エステル又は（及び）メタクリル酸エステ
ルの共重合に関与する成分の量が他の単量体の共
重合に関与する成分の量よりも多くされているこ
とが好ましい。 Pressure-sensitive adhesives are polymers containing acrylic esters and/or methacrylic esters because they do not have chemically active groups and do not cause strong irritation to the skin. This is because it can prevent a decrease in drug efficacy due to interactions with drugs. For this purpose, if the polymer is a copolymer of acrylic ester or (and) methacrylic ester and another monomer copolymerizable with these, acrylic ester or (and) methacrylic ester It is preferable that the amount of the component involved in the copolymerization of the acid ester is greater than the amount of the component involved in the copolymerization of other monomers.
感圧性接着剤を製造するに際しては、通常のラ
ジカル重合触媒、例えばアゾピス系化合物、過酸
化物系化合物を用いるのが好適である。 When producing a pressure-sensitive adhesive, it is preferable to use a common radical polymerization catalyst, such as an azopis compound or a peroxide compound.
又、重合形態は、溶液重合、バルク重合、エマ
ルジヨン重合、懸濁重合等を行なえばよいが、後
工程となる薬剤の混合、溶解工程を考えると溶液
重合が最適である。 The polymerization may be carried out by solution polymerization, bulk polymerization, emulsion polymerization, suspension polymerization, etc., but solution polymerization is most suitable in consideration of the subsequent steps of mixing and dissolving the drug.
例えば反応容器内に、アクリル酸エステル、メ
タクリル酸エステルの単量体、酢酸エチル等の溶
媒を加えて約60重量％濃度の溶液となし、反応容
器内の雰囲気を窒素ガスで置換し、撹拌しながら
昇温し、60乃至80℃の温度において、ラジカル発
生触媒を同じ溶媒によつて溶解した溶液を滴下す
るか分割注入し、粘度の上昇に応じて溶媒のみを
追加しながら粘度を抑制し、全体として10乃至20
時間で重合を完了する。このようにして感圧性接
着剤の溶液が作成された後、これに界面活性剤
と、弱酸基又は強酸基の金属塩を有する薬剤が含
有される。感圧性接着剤層に含有される界面活性
剤としては、アニオン系界面活性剤、及びアニオ
ン−ノニオン系界面活性剤が使用に適する。アニ
オン系界面活性剤としては、例えばラウリル硫酸
ナトリウム、ドデシルベンゼンスルホン酸ナトリ
ウム、アルキルジフエニルエーテルジスルホン酸
ナトリウム、ジオクチルスルホコハク酸塩、脂肪
酸ソーダ、オレイルメチルタウリン酸ナトリウ
ム、ラウリルメチルタウリン酸ナトリウム、ラウ
ロイルザルコミネート、アルキルサルフエート、
オリゴマータイプのスチレン無水マレイン酸半ア
ルキルエステル共重合体等が用いられる。アニオ
ン−ノニオン系界面活性剤としては例えばポリオ
キシアルキルフエニルエーテルサルフエートアン
モニウム塩等が用いられる。感圧性接着剤層に含
有される界面活性剤は、感圧性接着剤と薬剤との
相溶性を良好にし、薬剤が感圧性接着剤層の表面
に析出するのを防止し、又感圧性接着剤層から滲
出する薬剤を徐々に患部へ移行させる役割を有す
る。 For example, add acrylic ester, methacrylic ester monomers, and a solvent such as ethyl acetate to a reaction container to make a solution with a concentration of about 60% by weight, replace the atmosphere in the reaction container with nitrogen gas, and stir. At a temperature of 60 to 80°C, a solution of the radical generating catalyst dissolved in the same solvent is dropped or injected in portions, and as the viscosity increases, only the solvent is added to suppress the viscosity. Overall 10-20
Polymerization is completed in hours. After the pressure-sensitive adhesive solution has been created in this way, it contains a surfactant and an agent having a metal salt of a weak or strong acid group. As the surfactant contained in the pressure-sensitive adhesive layer, anionic surfactants and anionic-nonionic surfactants are suitable for use. Examples of anionic surfactants include sodium lauryl sulfate, sodium dodecylbenzene sulfonate, sodium alkyl diphenyl ether disulfonate, dioctyl sulfosuccinate, sodium fatty acid, sodium oleyl methyl taurate, sodium lauryl methyl taurate, and sodium lauryl sulfonate. nate, alkyl sulfate,
An oligomer type styrene maleic anhydride semi-alkyl ester copolymer or the like is used. As the anionic-nonionic surfactant, for example, polyoxyalkyl phenyl ether sulfate ammonium salt or the like is used. The surfactant contained in the pressure-sensitive adhesive layer improves the compatibility between the pressure-sensitive adhesive and the drug, prevents the drug from depositing on the surface of the pressure-sensitive adhesive layer, and improves the compatibility between the pressure-sensitive adhesive and the drug. Its role is to gradually transfer the drug exuding from the layer to the affected area.
薬剤としては弱酸基又は強酸基の金属塩を有す
るものが使用される。かゝる薬剤は、そのまゝで
はアクリル酸エステル又は（及び）メタクリル酸
エステルを構成成分とする重合体よりなる感圧性
接着剤と相溶せず、感圧性接着剤層の表面に析出
してくるという欠点を有するものであり、治療用
接着テープもしくはシートとして必要とされる薬
剤の滲出性が悪いものにしかなり得なかつたもの
である。しかしながら本発明では界面活性剤と弱
酸基又は強酸基の金属塩を有する薬剤を併用する
ことにより、薬剤と感圧性接着剤との相溶性が良
好になり、薬剤が感圧性接着剤層の表面に析出す
るのが防止されると同時に、薬剤が患部に徐々に
吸収されるものとなる。 As the drug, one having a metal salt of a weak acid group or a strong acid group is used. Such agents are not compatible with pressure-sensitive adhesives made of polymers containing acrylic esters and/or methacrylic esters as they are, and may precipitate on the surface of the pressure-sensitive adhesive layer. However, the adhesive tape or sheet used for treatment can only have poor exudation properties of the drug required for the adhesive tape or sheet. However, in the present invention, by using a surfactant and a drug having a metal salt of a weak acid group or a strong acid group, the compatibility between the drug and the pressure-sensitive adhesive is improved, and the drug is applied to the surface of the pressure-sensitive adhesive layer. Precipitation is prevented and, at the same time, the drug is gradually absorbed into the affected area.
弱酸基又は強酸基の金属塩を有する薬剤の量
は、感圧性接着剤層の厚み、薬剤の種類等により
異なるが、感圧性接着剤層１cm2当り１〜1000mgの
範囲とされるのが好適である。 The amount of the drug having a metal salt of a weak acid group or a strong acid group varies depending on the thickness of the pressure-sensitive adhesive layer, the type of drug, etc., but is preferably in the range of 1 to 1000 mg per 1 cm 2 of the pressure-sensitive adhesive layer. It is.
弱酸基の金属塩を有する薬剤としては、例えば
インドメタシンのナトリウム塩、サリチル酸のナ
トリウム塩、ゴールドチオマレイン酸ナトリウム
のナトリウム塩等のカルボン酸基のアルカリ金属
塩を有する薬剤、メナジオールジフオスフエート
のナトリウム塩、トリクロロエチルフオスフエー
トのナトリウム塩等のリン酸基のアルカリ金属
塩、メナジオンスルホン酸ソーダ等のスルホン酸
基のアルカリ金属塩等を有する薬剤が使用に適す
る。 Examples of drugs having a metal salt of a weak acid group include drugs having an alkali metal salt of a carboxylic acid group such as sodium salt of indomethacin, sodium salt of salicylic acid, sodium salt of gold thiomaleate, and menadiol diphosphate. Agents having alkali metal salts of phosphoric acid groups, such as sodium salts, sodium salts of trichloroethyl phosphate, and alkali metal salts of sulfonic acid groups, such as menadione sodium sulfonate, are suitable for use.
かくして得られる治療用接着テープもしくはシ
ートは、患部に貼付されると、例えば10〜24時間
程度の時間をかけて徐々に滲出し、患部に吸収さ
れる。 When the therapeutic adhesive tape or sheet thus obtained is applied to the affected area, it gradually oozes out and is absorbed into the affected area over a period of, for example, about 10 to 24 hours.
本発明治療用接着テープもしくはシートによれ
ば、感圧性接着剤薬剤との相溶性が良好であり、
患部に貼付した際に薬剤が感圧性接着剤層から患
部へ徐々に滲出し、良好な治療効果を上げること
ができるものとなる。 According to the therapeutic adhesive tape or sheet of the present invention, it has good compatibility with pressure-sensitive adhesive drugs,
When applied to the affected area, the drug gradually oozes out from the pressure-sensitive adhesive layer to the affected area, resulting in good therapeutic effects.
実施例 １
２−エチルヘキシルメタクリレート 39.6ｇ
２−エチルヘキシルアクリレート 18.4ｇ
ｎ−ブチルアクリレート 25.6ｇ
上記各成分を、反応装置に投入し、窒素ガスで
置換した後、撹拌しつつ加熱し、70℃まで昇温し
た。Example 1 2-ethylhexyl methacrylate 39.6g 2-ethylhexyl acrylate 18.4g n-butyl acrylate 25.6g The above components were introduced into a reactor, and after replacing the atmosphere with nitrogen gas, the mixture was heated with stirring and the temperature was raised to 70°C. did.
次いで、
アゾビスイソブチロニトリル 0.5ｇ
酢酸エチル 70ml
よりなる触媒溶液を滴下ロートに準備し、反応液
を70℃に保ちつつ、14時間をかけて７回にわけ
て、等量ずつ注入した。 Next, a catalyst solution consisting of 0.5 g of azobisisobutyronitrile and 70 ml of ethyl acetate was prepared in the dropping funnel, and while the reaction solution was kept at 70° C., equal amounts were injected into the solution in 7 portions over 14 hours.
この間、重量が進むにつれ増粘したので、酢酸
エチルを30mlずつ２回にわたつて追加投入した。 During this time, the viscosity increased as the weight increased, so ethyl acetate was added twice in 30 ml portions.
触媒の注入完了後、液温を還流温度（78.5℃）
まで上げ、更に４時間撹拌を続け、重合反応を完
了した。こうして得た重合体溶液（固形分15.0
％）100ｇに界面活性剤としてラウリル硫酸ナト
リウム0.15ｇ、薬剤としてサリチル酸ナトリウム
1.5ｇを混合した溶液を得た。 After the catalyst injection is completed, the liquid temperature is reduced to reflux temperature (78.5℃)
The polymerization reaction was completed by increasing the temperature to 100% and stirring was continued for an additional 4 hours. The polymer solution thus obtained (solid content 15.0
%) 100g contains 0.15g of sodium lauryl sulfate as a surfactant and sodium salicylate as a drug.
A mixed solution of 1.5 g was obtained.
この溶液をコロナ放電処理したエチレン−酢酸
ビニル共重合体のフイルム上に塗布し、70℃で10
分間をかけて乾燥し、感圧性接着剤層を形成し
た。得られた感圧性接着剤層の厚みは50.2μｍで
１cm2当り400μｇのサリチル酸ナトリウムが含有
されていた。 This solution was applied onto a film of ethylene-vinyl acetate copolymer treated with corona discharge, and then heated at 70℃ for 10 minutes.
It was dried for several minutes to form a pressure sensitive adhesive layer. The resulting pressure-sensitive adhesive layer had a thickness of 50.2 μm and contained 400 μg of sodium salicylate per cm 2 .
かくして得られた治療用接着テープを製造直後
と60℃で１週間放置したものについて、サリチル
酸ナトリウムの相溶状態を観察したところ、いず
れの場合もサリチル酸ナトリウムの折出は認めら
れず、相溶性がすぐれていた。 When we observed the state of compatibility of sodium salicylate in the thus obtained therapeutic adhesive tape immediately after production and after leaving it at 60°C for one week, no precipitation of sodium salicylate was observed in either case, indicating that the compatibility was poor. It was excellent.
またこの治療用接着テープもしくはシートを直
径66mmの円盤状に打抜いて得られた試料をシヤー
レに水50mlを入れて浸漬し、サリチル酸ナトリウ
ムを油出した。１時間後、３時間後、６時間後、
12時間後、24時間後に試料から放出されたサリチ
ル酸ナトリウムの量を高速液体クロマトグラフイ
ーにより定量した結果、夫々、3.82mg、7.64mg、
11.05mg、12.83mg、13.50mgであつた。この試料中
に含有されているサリチル酸ナトリウムの量は
13.68mgであるから、サリチル酸ナトリウムが
徐々に好ましい速度で滲出され、24時間後には
ほゞ全て滲出されていることが確認された。 Further, a sample obtained by punching out this therapeutic adhesive tape or sheet into a disk shape with a diameter of 66 mm was immersed in 50 ml of water in a shear dish to extract the sodium salicylate. 1 hour later, 3 hours later, 6 hours later,
The amount of sodium salicylate released from the sample after 12 hours and 24 hours was determined by high performance liquid chromatography, and the results were 3.82 mg, 7.64 mg, and 7.64 mg, respectively.
They were 11.05mg, 12.83mg, and 13.50mg. The amount of sodium salicylate contained in this sample is
Since the amount of sodium salicylate was 13.68 mg, it was confirmed that sodium salicylate was gradually exuded at a favorable rate, and that almost all of it was exuded after 24 hours.
実施例 ２
２−エチルヘキシルメタクリレート 39.6ｇ
２−エチルヘキシルアクリレート 36.8ｇ
ｎ−ブチルアクリレート 25.6ｇ
上記の各成分を実施例１と同様にして反応させ
て得られた重合体溶液（固形分18.9％）100ｇに、
界面活性剤としてポリオキシアルキルフエニルエ
ーテルサルフエートアンモニウム塩0.189ｇと薬
剤としてサリチル酸ナトリウム1.89ｇを混合した
溶液を得た。この溶液を用いて実施例１と同様に
してポリエチレンフイルムに感圧性接着剤層を形
成した。Example 2 2-ethylhexyl methacrylate 39.6g 2-ethylhexyl acrylate 36.8g n-butyl acrylate 25.6g To 100g of a polymer solution (solid content 18.9%) obtained by reacting each of the above components in the same manner as in Example 1 ,
A solution containing 0.189 g of polyoxyalkylphenyl ether sulfate ammonium salt as a surfactant and 1.89 g of sodium salicylate as a drug was obtained. Using this solution, a pressure-sensitive adhesive layer was formed on a polyethylene film in the same manner as in Example 1.
得られた感圧性接着剤層の厚みは53.4μｍで１
cm2当り425μｇのサリチル酸ナトリウムが含有さ
れていた。 The thickness of the pressure-sensitive adhesive layer obtained was 53.4 μm and 1
It contained 425 μg of sodium salicylate per cm 2 .
かくして得られた治療用接着テープを製造直後
と60℃で20日間放置したものについて感圧性接着
剤とサリチル酸ナトリウムの相溶状態を観際した
ところ、いずれの場合もサリチル酸ナトリウムの
析出は認められず相溶性がすぐれていた。又実施
例１と同様にしてサリチル酸ナトリウムの滲出性
をみたが、徐々に好ましい速度でテープから滲出
されていることが確認された。 When the compatibility state of the pressure-sensitive adhesive and sodium salicylate was observed for the thus obtained therapeutic adhesive tape immediately after production and after being left at 60°C for 20 days, no precipitation of sodium salicylate was observed in either case. They had excellent compatibility. In addition, the exudation property of sodium salicylate was examined in the same manner as in Example 1, and it was confirmed that the sodium salicylate was exuded gradually from the tape at a preferable rate.
実施例 ３
２−エチルヘキシルメタクリレート 39.6ｇ
ｎ−ブチルアクリレート 38.4ｇ
上記の各成分を実施例１と同様にして反応させ
て得られた重合体溶液（固形分20.3％）100ｇに、
界面活性剤としてドデシルベンゼンスルホン酸ナ
トリウム0.203ｇと、薬剤としてインドメタシン
のナトリウム塩4.06ｇを混合溶解した。この溶液
を用いて実施例１と同様にしてポリエチレンフイ
ルム上に感圧性接着剤層を形成した。得られた感
圧性接着剤層の厚みは、45.8μｍであつた。Example 3 2-ethylhexyl methacrylate 39.6g n-butyl acrylate 38.4g To 100g of a polymer solution (solid content 20.3%) obtained by reacting each of the above components in the same manner as in Example 1,
0.203 g of sodium dodecylbenzenesulfonate as a surfactant and 4.06 g of sodium salt of indomethacin as a drug were mixed and dissolved. Using this solution, a pressure-sensitive adhesive layer was formed on a polyethylene film in the same manner as in Example 1. The thickness of the pressure-sensitive adhesive layer obtained was 45.8 μm.
かくして得られた治療用接着テープを製造直後
と、60℃で20日間放置したものについて、感圧性
接着剤とインドメタシンのナトリウム塩との相溶
状態を観察したが、インドメタシンのナトリウム
塩の析出は認められず相溶性がすぐれていた。 The compatibility state of the pressure-sensitive adhesive and the sodium salt of indomethacin was observed for the thus obtained therapeutic adhesive tape immediately after production and for the tape that had been left at 60°C for 20 days, but no precipitation of the sodium salt of indomethacin was observed. The compatibility was excellent.
又実施例１と同様にしてインドメタシンのナト
リウム塩を水中に油出し、これを定量した結果１
時間後に2.82mg、３時間後6.50mg、６時間後に
7.73mg、12時間後に8.59mg、24時間後に9.01mgで
あり、感圧性接着剤層中のインドメタシンのナト
リウム塩は徐々に滲出され、24時間後には殆んど
滲出されていることが確認された。 In addition, in the same manner as in Example 1, the sodium salt of indomethacin was extracted into water and the amount was quantified.
2.82mg after 3 hours, 6.50mg after 3 hours, 6 hours after
7.73 mg, 8.59 mg after 12 hours, and 9.01 mg after 24 hours, and it was confirmed that the sodium salt of indomethacin in the pressure-sensitive adhesive layer was gradually leached out, and almost all of it was leached out after 24 hours. .
比較例 １
２−エチルヘキシルメタクリレート 39.6ｇ
ｎ−ブチルアクリレート 38.4ｇ
上記の各成分を実施例１と同様にして反応させ
て得られた重合体溶液（固形分20.3％）100ｇに
薬剤としてインドメタシンのナトリウム塩4.06ｇ
を混合した溶液を得た。Comparative Example 1 2-ethylhexyl methacrylate 39.6g n-butyl acrylate 38.4g Indomethacin sodium salt as a drug was added to 100g of a polymer solution (solid content 20.3%) obtained by reacting the above components in the same manner as in Example 1. 4.06g
A mixed solution was obtained.
この溶液を用いて実施例１と同様にしてポリエ
チレンフイルム上に感圧性接着剤層を形成した。
得られた感圧性接着剤層の厚みは47.5μｍであつ
た。 Using this solution, a pressure-sensitive adhesive layer was formed on a polyethylene film in the same manner as in Example 1.
The thickness of the pressure-sensitive adhesive layer obtained was 47.5 μm.
かくして得られた治療用接着テープを製造直後
のものについて観察したところインドメタシンの
ナトリウム塩の析出がほゞ全面的に認められた。 When the therapeutic adhesive tape thus obtained was observed immediately after production, precipitation of the sodium salt of indomethacin was observed almost entirely.
又、実施例１と同様にしてインドメタシンのナ
トリウムを水中に抽出しこれを定量した結果、３
時間後に9.51mgが抽出されており、短時間でほゞ
全量が抽出されてしまうことが認められた。 In addition, in the same manner as in Example 1, the sodium of indomethacin was extracted into water and quantified.
After an hour, 9.51 mg was extracted, indicating that almost the entire amount was extracted in a short period of time.
Claims (1)
タクリル酸エステルを構成成分とする重合体より
なる感圧性接着剤層が設けられ、該感圧性接着剤
層に界面活性剤と、弱酸基又は強酸基の金属塩を
有する薬剤が含有されている、治療用接着テープ
もしくはシート。 ２ 界面活性剤が、アニオン系又はアニオン−ノ
ニオン系のものである、特許請求の範囲第１項記
載の治療用接着テープもしくはシート。[Claims] 1. A pressure-sensitive adhesive layer made of a polymer containing an acrylic ester or (and) a methacrylic ester as a constituent is provided on a base material, and the pressure-sensitive adhesive layer is provided with a surfactant and a polymer. A therapeutic adhesive tape or sheet containing a drug having a metal salt of a weak acid group or a strong acid group. 2. The therapeutic adhesive tape or sheet according to claim 1, wherein the surfactant is anionic or anionic-nonionic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57052671A JPS58168680A (en) | 1982-03-30 | 1982-03-30 | Adhesive tape or sheet for therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57052671A JPS58168680A (en) | 1982-03-30 | 1982-03-30 | Adhesive tape or sheet for therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58168680A JPS58168680A (en) | 1983-10-05 |
| JPH0131388B2 true JPH0131388B2 (en) | 1989-06-26 |
Family
ID=12921328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57052671A Granted JPS58168680A (en) | 1982-03-30 | 1982-03-30 | Adhesive tape or sheet for therapy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58168680A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3888791T3 (en) * | 1987-11-19 | 1999-07-29 | Exxon Chemical Patents Inc | Thermoplastic films for use in stretch and adhesion applications. |
| JP2002317164A (en) * | 2001-04-18 | 2002-10-31 | Nippon Fuirin Kk | Water-base pressure-sensitive adhesive |
| US20050249791A1 (en) * | 2004-05-07 | 2005-11-10 | 3M Innovative Properties Company | Antimicrobial articles |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5645412A (en) * | 1979-09-20 | 1981-04-25 | Nitto Electric Ind Co Ltd | Medicinal material |
| JPS5687519A (en) * | 1979-12-19 | 1981-07-16 | Nitto Electric Ind Co Ltd | Drug pharmaceutical |
| JPS577409A (en) * | 1980-06-14 | 1982-01-14 | Nitto Electric Ind Co Ltd | Plaster |
-
1982
- 1982-03-30 JP JP57052671A patent/JPS58168680A/en active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5645412A (en) * | 1979-09-20 | 1981-04-25 | Nitto Electric Ind Co Ltd | Medicinal material |
| JPS5687519A (en) * | 1979-12-19 | 1981-07-16 | Nitto Electric Ind Co Ltd | Drug pharmaceutical |
| JPS577409A (en) * | 1980-06-14 | 1982-01-14 | Nitto Electric Ind Co Ltd | Plaster |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58168680A (en) | 1983-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0062682A1 (en) | Adhesive preparation for heart disease and process for its preparation | |
| EP0181970B1 (en) | Percutaneously administrable pharmaceutical preparation in the form of an adhesive tape | |
| NO171950B (en) | PROCEDURE FOR THE PREPARATION OF AN ADHESIVE LAYER FOR CONTINUOUS TRANSDERMAL ADMINISTRATION OF A PHARMACEUTICAL ACTIVE MEDICINE | |
| JPH0499720A (en) | Medicinal pharmaceutical for percutaneous administration | |
| JP6658201B2 (en) | Patch | |
| JPH0131388B2 (en) | ||
| JPS5939827A (en) | External member for medical use | |
| JP4988079B2 (en) | Transdermal preparation | |
| JPH0367043B2 (en) | ||
| JPH0369884B2 (en) | ||
| JPH0742228B2 (en) | Pharmaceutical formulation | |
| JPS6066759A (en) | Pharmaceutical preparation | |
| JPS6260102B2 (en) | ||
| JPS597689B2 (en) | pharmaceutical formulations | |
| CN102144991A (en) | Composition containing selegiline and transdermal patch containing composition | |
| JPS5867776A (en) | Adhesive tape or sheet for remedy | |
| JPS58134020A (en) | Pharmaceutical preparation | |
| JPH0363530B2 (en) | ||
| JPH0380768B2 (en) | ||
| JPH0530465B2 (en) | ||
| JPS6126967B2 (en) | ||
| CN103919754B (en) | Oxybutynin pharmaceutical composition and its application | |
| JPS6320410B2 (en) | ||
| JPS6069016A (en) | Sticky patch preparation | |
| JP4988078B2 (en) | Transdermal preparation |